VIDO funded $24M to help develop 'holy grail' coronavirus vaccine
Social Sharing
The Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan has been awarded a $24 million grant to help develop a vaccine to protect against wide-ranging strains of coronaviruses.
VIDO's funding flows from Norwegian-based Coalition for Epidemic Preparedness Innovations (CEPI) into its ongoing development of its pan-sarbecovirus vaccine.
Dr. Nicole Lurie, Executive Director of Emergency Preparedness at CEPI, said the vaccine is designed by combining fragments of several different coronaviruses into a single vaccine.
VIDO's goal is to develop a vaccine that would improve a person's resistance to SARS-CoV-1 and SARS-CoV-2, the virus that led to the COVID-19 pandemic, as well as future coronaviruses, limiting how much resources are spent on new vaccines to match different strains of the virus.
Lurie referred to it as a sort of "holy grail."
"By acting now, we can try to get ahead of coronavirus and their variants before they evolve to get ahead of us. Our goal is to be sure that the world is never again hit by a coronavirus pandemic," said Lurie.
Dr. Volker Gerdts, the director and CEO of VIDO said it's possible to use different tools — artificial intelligence, bioinformatics — to predict what the next virus pathogen will look like and prepare vaccines to combat them.
"It's all about predicting what is coming in the future and being ready for it," said Gerdts.
"As we just learned during the pandemic, Canada was not quite ready for it this time. So let's make sure that next time we're better prepared."
VIDO's vaccine is also anticipated to be thermostable, meaning it won't need to be in a temperature-controlled environment when it's transported or stored.
That opens it up to use in low- and middle-income countries and in regions with less resources to allow for better access to vaccines.
"We saw what the COVID pandemic did to our economy, did to our families, did to our small businesses and you know, we want to be prepared," said Terry Duguid, the federal Minister Responsible for Prairies Economic Development Canada (PrairiesCan).
PrairiesCan also provided VIDO with $30 million to expand, including a new animal housing facility and the ability to upgrade to the highest level of containment to work with any form of human or animal pathogen.
VIDO also received funding from CEPI in 2021 for an earlier project on a variant-proof COVID-19 vaccine.
The Coalition for Epidemic Preparedness was founded by the Indian and Norwegian governments, Bill and Melinda Gates Foundation, Wellcome and the World Economic Forum. It's supported by several pharmaceutical companies including Johnson & Johnson and Pfizer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Music festivals have become more open to harm reduction initiatives. How far will it go?
NEW YORK (AP) — The sounds of muffled percussion and audience cheers reverberate throughout the grounds. Brand activations, makeshift bars and restaurant pop-ups control traffic as a sea of bodies move from set to set. Sandwiched between is a row of nonprofits across familiar causes: hunger, housing and voter registration. It's a common music festival scene, until closer inspection. There is a new table, This Must Be the Place. The Ohio-based nonprofit offers attendees free opioid overdose reversal treatment and training on how to use it, an education acquired in under two minutes. Just a few years ago, their inclusion might've been unthinkable amid murky regulations and a lack of public awareness surrounding harm reduction. Advocates say drugs are commonly consumed at music festivals, making them ideal locations for harm reduction activities. While more music festivals are allowing such activities, activists are pushing for expanded efforts as some festivals remain cautious. Harm reduction varies at festivals across the country Founded by William Perry and Ingela Travers-Hayward in 2022, This Must Be The Place has since given away an estimated $4.5 million in naloxone, the opioid overdose reversal medication, at festivals and smaller community events. In the very beginning, without a 'proof of concept,' as Perry describes it, they had trouble partnering with festivals. Eventually, a few festivals in the Midwest agreed to let them table, which 'got us in the door with Bonnaroo in 2022,' says Perry, referring to the major U.S. festival operated by C3 Presents, one of the largest concert promoters on the planet. Now they have a presence at 35 major U.S. festivals — including Lollapalooza, Governors Ball and Besame Mucho — where they collaborate directly with C3 and their security personnel. The organization's growth overlaps with advancing federal regulations. According to Daliah Heller, vice president of overdose prevention initiatives at the global public health nonprofit Vital Strategies, naloxone distribution used to be determined by state regulations until 2023, when the Food and Drug Administration approved the first over-the-counter nasal spray. 'We no longer need the prescription laws to be amended to allow for the distribution of naloxone,' she says. 'Now it's like buying aspirin — it's over the counter.' Last year, This Must Be the Place gave away 46,146 units of Narcan — a brand name for naloxone — through their national festival outreach. Emmett Beliveau, chief operating officer of C3 Presents, says working with This Must Be the Place was C3's first time implementing public-facing harm reduction strategies, in addition to the promoter's existing medical programs. Bringing the organization into C3's festivals was 'not in response to anything that has happened at one of our festivals,' he says, but rather because of the 'number of fatalities happening in our communities.' Some attendees have taken matters into their own hands Some activists believe attendees are most responsive to receiving harm reduction education from peers instead of authority figures. And so, for the last three years, a nonprofit dedicated to combating accidental drug overdoses among young adults, Team Awareness Combating Overdose, has distributed fentanyl test strips and Narcan at the Coachella Valley Music and Arts Festival. Former TACO CEO Kameran Mody says that music festivals are ideal locations for distribution and education because 'music and the use of drugs are synonymous with each other.' TACO distributes through what Mody describes as 'guerrilla-style marketing.' They enlist volunteers, train them on how to use naloxone, and ship Narcan and test strips to them to bring into the festival. They do not involve the festival organizers. Representatives for Coachella did not respond to The Associated Press' requests for comment. In 2023, a TACO volunteer administered Narcan to an unresponsive Coachella attendee exhibiting signs of an overdose. The organization says the attendee regained consciousness. 'That was one of our biggest successes,' Mody says. Local laws and the risk of criminalization hinder initiatives In 2019, at Bonnaroo, a 27-year-old man was found dead at his campsite — right after harm reduction activists had picketed the Tennessee festival because it didn't allow drug testing. The toxicology report found ecstasy and fentanyl in his system. At the time, under state law, test strips were criminalized and classified as drug paraphernalia. That's changed: In 2022, Tennessee decriminalized fentanyl test strips. By the end of 2023, 44 other states and D.C. had done the same. But in some states, drug paraphernalia laws are written in a way that isn't completely transparent — there are test strips that are not fentanyl-specific, Heller points out — and criminalization and social stigmas endure. Some have found workarounds. 'Even in the states where the legalities were a bit unclear, instead of just coming in and hoping things worked out, we would reach out to the health department, and say 'We run this project, how do feel about it?'' says Perry. 'We would end up with letters from the highest-ranking health official, either in the county or in the state, saying 'We approve of this.' That circumvented any roadblocks.' Some festivals, though, might be hesitant to use test strips because 'it's tough for them to admit that drugs are being used,' Mody says. Some festivals have even banned naloxone. While This Must Be The Place distributes fentanyl test strips at some Ohio events, C3 doesn't distribute test strips at its events and does not plan to. Beliveau doesn't believe fentanyl test strips are effective and expressed concern they could encourage drug use. Test strips, which can detect fentanyl in pills, powders or injectables, are recommended by the Centers for Disease Control and Prevention as a low-cost means of helping prevent drug overdoses. Harm reduction shows promise outside the US At a three-day electronic music festival in Mexico City earlier this year, a booth provided free, anonymous drug testing. The initiative, known as 'Checa tu Sustancia' (Check Your Substance), was spearheaded by the Instituto RIA, a Mexico-based drug policy research and advocacy organization. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. When unexpected substances are detected, users received detailed information on what they are, their risks, potential interactions with other substances and dosage adjustments, empowering them to make informed choices. Perry says they are aware of smaller festivals in the United States conducting drug checking, but 'they do it in a very underground and whisper network way' to avoid criminalization. What Perry says his organization would like to see at music festivals in the future would be harm reduction areas — sections where attendees who have taken drugs can be monitored, not to 'get them into trouble' but to ensure safety. Heller says there are a number of groups working to destigmatize drugs, promote decriminalization, and promote drug checking. 'We already have drug checking happening in cities,' she says. 'It makes perfect sense to expand the settings where you would offer that to include music festivals. It's the same rationale. … The issue is this idea of liability. You'd have to create a law, essentially, that would protect the festival from liability.'
Toronto Star
3 hours ago
- Toronto Star
The caveman skincare trend on TikTok is clean beauty at its worst
The Paleo trend has come for your face: ' Caveman skin' is the latest beauty routine taking over social media. After circulating on Reddit for a few years, it was popularized this spring by Montreal-based TikTokker Tia Zakher, who went viral on the app for going about three months without putting anything on her face — no water, no cleanser, no moisturizer, nothing. The idea is that it's an elimination diet for your skin; an epidermal reset, if you will. 'For years, I picked and over-exfoliated and damaged my skin really badly … My skin is basically shedding all the damage and attempting to reregulate itself,' Zakher says in a video about the trend. Over the course of her attempt, which she says she did with guidance from her dermatologist, her skin looks as if it's pilling and then peeling off.
Cision Canada
3 hours ago
- Cision Canada
Avant Technologies Signs Letter of Intent for a Business Combination
LAS VEGAS, June 10, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), today announced that it has entered into a non-binding letter of intent ("LOI") for a potential business combination with Ainnova Tech, Inc. (Ainnova). Ainnova, the Company's joint venture partner, is a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI). Ainnova's technology portfolio includes its cutting-edge AI-powered platform technology, Vision AI, several key algorithms, and its proprietary automated retinal camera, which is currently in development. Under the terms of the LOI, Avant and Ainnova would become a combined entity, with Ainnova rolling 100% of its outstanding equity and equity equivalents—or all its business—into the combined public company, with the deal structure to be determined later by the parties based on further due diligence findings and other considerations. Avant and Ainnova expect to announce additional details regarding the business combination when a definitive agreement is executed, which is expected in late June or early next quarter. Any transaction would be subject to board and equity holder approval of both companies, regulatory approvals, and other customary conditions. Avant and Ainnova executives believe that now is the time to strengthen their partnership and merge into a single entity before the Company's pre-submission meeting with the U.S. Food and Drug Administration in early July, in preparation for the planned clinical trial of Ainnova's Vision AI platform for early detection of diabetic retinopathy. In late 2024, the two companies formed Ai-nova Acquisition Corp. (AAC) to advance and commercialize Ainnova's technology portfolio. During that time, the two companies completed further due diligence and focused on an opportunity to work together as one company. The Board of Directors and management team of Avant remain fully committed to executing the Company's strategic plan, which is focused on enhancing long-term value. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., said of the business combination, "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare." About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI—our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
